Dr. Jeffrey L. Cummings In The News

Profile: Dr. Jeffrey L. Cummings

September 13, 2021
Resverlogix Corp., a world leader in epigenetics, or gene regulation, announces today new data that demonstrates their first-in-class oral small molecule BET inhibitor candidate Apabetalone significantly improves cognition and reduces cognitive decline among high-risk patients with cardiovascular disease and diabetes mellitus.
August 19, 2021
Approval of aducanumab will herald a new era in Alzheimer’s disease care and research.
August 16, 2021
The Food and Drug Administration’s controversial June 7 approval of aducanumab (Aduhelm) means that for the first time in 18 years, Alzheimer’s patients have a new treatment option.
August 10, 2021
NervGen Pharma Corp., a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced yesterday it has entered into a research collaboration with Dr. Ksenia Kastanenka of Massachusetts General Hospital (MGH) to study the effects of NervGen’s lead compound, NVG-291, in validated animal models of Alzheimer’s disease.
August 9, 2021
NervGen Pharma Corp., a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced today it has entered into a research collaboration with Dr. Ksenia Kastanenka of Massachusetts General Hospital (MGH) to study the effects of NervGen's lead compound, NVG-291, in validated animal models of Alzheimer's disease.
August 6, 2021
The Food and Drug Administration’s approval of Biogen and Eisai’s anti-amyloid antibody aducanumab on June 7 left many questions unanswered, including how to use the drug in clinical practice.
August 4, 2021
Many doctors appear uneasy about prescribing Aduhelm, as they continue to grapple with a long list of unknowns.
August 3, 2021
Many doctors appear uneasy about prescribing Aduhelm, as they continue to grapple with a long list of unknowns.